eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2013
vol. 17
 
Share:
Send email
Share:
abstract:
Original paper

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis

Katarzyna Wiater
,
Tomasz Świtaj
,
Jacek Mackiewicz
,
Ewa Kalinka-Warzocha
,
Marek Wojtukiewicz
,
Paweł Szambora
,
Sławomir Falkowski
,
Wojciech Rogowski
,
Andrzej Mackiewicz
,
Piotr Rutkowski

Wspolczesna Onkol 2013; 17 (3): 257–262
DOI: https://doi.org/10.5114/wo.2013.35785
Online publish date: 2013/06/28
View full text Get citation
 
PlumX metrics:
Aim of the study: The Patient Assistance Program, a type of expanded access program, was initiated for compassionate purposes to provide ipilimumab to patients with unresectable stage III or

IV melanoma with failed previous treatment. The aim of this analysis is to evaluate efficacy, safety, and tolerability of ipilimumab therapy in daily clinical practice.

Material and methods: We analyzed

50 patients (29 males, 21 females) aged 21 to 76 years (median: 49 years). An ipilimumab dose of 3 mg/kg was administered intravenously every 3 weeks for a total of 4 doses. Patients were assessed for response rate, progression-free survival and overall survival, and monitored for adverse events.

Results: The objective response (complete or partial response) rate was 12%. Median overall survival was 8 months and median progression-free survival was 3 months. In patients with ECOG-PS 0, the median overall survival was 16 months. Immune-related adverse events (irAEs) occurred in 48% of the patients, grade 3 or 4 irAEs were reported in 8% of the patients, and there were no toxic deaths.

Conclusions: Ipilimumab demonstrated clinical benefit in previously treated advanced melanoma patients. Although clinical benefit is limited to a minority of the patients, there is a benefit in terms of overall survival in this group of pa­tients.
keywords:

melanoma, ipilimumab, CTLA-4, immunotherapy, outcome
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.